Abhishek Kumar1,2,3, Nagarajan Paramasivam4, Kari Hemminki1,5,6, Asta Försti7,8,9, Obul Reddy Bandapalli1,10,11, Matthias Schlesner12, Tianhui Chen13, Rolf Sijmons14, Dagmara Dymerska15, Katarzyna Golebiewska15, Magdalena Kuswik15, Jan Lubinski15. 1. Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany. 2. Institute of Bioinformatics, International Technology Park, Bangalore, 560066, India. 3. Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, 576104, India. 4. Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases (NCT), Heidelberg, Germany. 5. Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, 30605, Pilsen, Czech Republic. 6. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 7. Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany. a.foersti@kitz-heidelberg.de. 8. Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany. a.foersti@kitz-heidelberg.de. 9. Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Im Neuenheimer Feld 580, 69120, Heidelberg, Germany. a.foersti@kitz-heidelberg.de. 10. Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany. 11. Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Im Neuenheimer Feld 580, 69120, Heidelberg, Germany. 12. Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), Heidelberg, Germany. 13. Department of Cancer Prevention, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, China. 14. Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 15. Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, 70-111, Szczecin, Poland.
Abstract
BACKGROUND: The most frequently identified strong cancer predisposition mutations for colorectal cancer (CRC) are those in the mismatch repair (MMR) genes in Lynch syndrome. Laboratory diagnostics include testing tumors for immunohistochemical staining (IHC) of the Lynch syndrome-associated DNA MMR proteins and/or for microsatellite instability (MSI) followed by sequencing or other techniques, such as denaturing high performance liquid chromatography (DHPLC), to identify the mutation. METHODS: In an ongoing project focusing on finding Mendelian cancer syndromes we applied whole-exome/whole-genome sequencing (WES/WGS) to 19 CRC families. RESULTS: Three families were identified with a pathogenic/likely pathogenic germline variant in a MMR gene that had previously tested negative in DHPLC gene variant screening. All families had a history of CRC in several family members across multiple generations. Tumor analysis showed loss of the MMR protein IHC staining corresponding to the mutated genes, as well as MSI. In family A, a structural variant, a duplication of exons 4 to 13, was identified in MLH1. The duplication was predicted to lead to a frameshift at amino acid 520 and a premature stop codon at amino acid 539. In family B, a 1 base pair deletion was found in MLH1, resulting in a frameshift and a stop codon at amino acid 491. In family C, we identified a splice site variant in MSH2, which was predicted to lead loss of a splice donor site. CONCLUSIONS: We identified altogether three pathogenic/likely pathogenic variants in the MMR genes in three of the 19 sequenced families. The MLH1 variants, a duplication of exons 4 to 13 and a frameshift variant, were novel, based on the InSiGHT and ClinVar databases; the MSH2 splice site variant was reported by a single submitter in ClinVar. As a variant class, duplications have rarely been reported in the MMR gene literature, particularly those covering several exons.
BACKGROUND: The most frequently identified strong cancer predisposition mutations for colorectal cancer (CRC) are those in the mismatch repair (MMR) genes in Lynch syndrome. Laboratory diagnostics include testing tumors for immunohistochemical staining (IHC) of the Lynch syndrome-associated DNA MMR proteins and/or for microsatellite instability (MSI) followed by sequencing or other techniques, such as denaturing high performance liquid chromatography (DHPLC), to identify the mutation. METHODS: In an ongoing project focusing on finding Mendelian cancer syndromes we applied whole-exome/whole-genome sequencing (WES/WGS) to 19 CRC families. RESULTS: Three families were identified with a pathogenic/likely pathogenic germline variant in a MMR gene that had previously tested negative in DHPLC gene variant screening. All families had a history of CRC in several family members across multiple generations. Tumor analysis showed loss of the MMR protein IHC staining corresponding to the mutated genes, as well as MSI. In family A, a structural variant, a duplication of exons 4 to 13, was identified in MLH1. The duplication was predicted to lead to a frameshift at amino acid 520 and a premature stop codon at amino acid 539. In family B, a 1 base pair deletion was found in MLH1, resulting in a frameshift and a stop codon at amino acid 491. In family C, we identified a splice site variant in MSH2, which was predicted to lead loss of a splice donor site. CONCLUSIONS: We identified altogether three pathogenic/likely pathogenic variants in the MMR genes in three of the 19 sequenced families. The MLH1 variants, a duplication of exons 4 to 13 and a frameshift variant, were novel, based on the InSiGHT and ClinVar databases; the MSH2 splice site variant was reported by a single submitter in ClinVar. As a variant class, duplications have rarely been reported in the MMR gene literature, particularly those covering several exons.
Authors: P Lichtenstein; N V Holm; P K Verkasalo; A Iliadou; J Kaprio; M Koskenvuo; E Pukkala; A Skytthe; K Hemminki Journal: N Engl J Med Date: 2000-07-13 Impact factor: 91.245
Authors: Ivo F A C Fokkema; Peter E M Taschner; Gerard C P Schaafsma; J Celli; Jeroen F J Laros; Johan T den Dunnen Journal: Hum Mutat Date: 2011-02-22 Impact factor: 4.878
Authors: Dagmara Dymerska; Pablo Serrano-Fernández; Janina Suchy; Andrzej Pławski; Ryszard Słomski; Krzysztof Kaklewski; Rodney J Scott; Jacek Gronwald; Józef Kładny; Tomasz Byrski; Tomasz Huzarski; Jan Lubiński; Grzegorz Kurzawski Journal: J Mol Diagn Date: 2009-12-10 Impact factor: 5.568
Authors: Lorelei A Mucci; Jacob B Hjelmborg; Jennifer R Harris; Kamila Czene; David J Havelick; Thomas Scheike; Rebecca E Graff; Klaus Holst; Sören Möller; Robert H Unger; Christina McIntosh; Elizabeth Nuttall; Ingunn Brandt; Kathryn L Penney; Mikael Hartman; Peter Kraft; Giovanni Parmigiani; Kaare Christensen; Markku Koskenvuo; Niels V Holm; Kauko Heikkilä; Eero Pukkala; Axel Skytthe; Hans-Olov Adami; Jaakko Kaprio Journal: JAMA Date: 2016-01-05 Impact factor: 56.272
Authors: N Jewel Samadder; Douglas Riegert-Johnson; Lisa Boardman; Deborah Rhodes; Myra Wick; Scott Okuno; Katie L Kunze; Michael Golafshar; Pedro L S Uson; Luke Mountjoy; Natalie Ertz-Archambault; Neej Patel; Eduardo A Rodriguez; Blanca Lizaola-Mayo; Michael Lehrer; Cameron S Thorpe; Nathan Y Yu; Edward D Esplin; Robert L Nussbaum; Richard R Sharp; Cindy Azevedo; Margaret Klint; Megan Hager; Sarah Macklin-Mantia; Alan H Bryce; Tanios S Bekaii-Saab; Aleksandar Sekulic; A Keith Stewart Journal: JAMA Oncol Date: 2021-02-01 Impact factor: 31.777